Notch1-mediated enrichment of drug efflux transporters and CSC population after chemotherapy was also described for NSCLC; however, DAPT pretreatment negatively influenced cisplatin-induced CD133+ cell selection and increased the sensitivity to doxorubicin and paclitaxel [186]. This evidence concerns the gene PROM1 and non-small cell lung carcinoma.